Targeting Bad Cells with Toxic Antibodies for Cancer and Autoimmune Disease

This patent describes special antibodies equipped with a toxic payload that specifically seek out and bind to unique markers on diseased cells, like cancer or autoimmune cells, to destroy them.

What it covers

This patent describes a specialized antibody, called an immunoglobulin, that carries a toxic substance, or 'toxic moiety' (Claim 1). This antibody is designed to specifically attach to a unique flag, an 'MHC-peptide complex,' that is found mostly on 'aberrant cells' – which are diseased cells like cancer or those involved in autoimmune conditions (Claim 1). The toxic substance can be chemically attached to the antibody or even built into it at the genetic level as a 'fusion protein' (Claims 6, 7). The goal is to deliver this toxic payload directly to the aberrant cells, potentially even getting the toxin inside them (Claim 10), to treat diseases like cancer (Claim 11). For example, an antibody could be engineered to find a specific MHC-peptide complex on a melanoma cell, then deliver a cell-killing drug directly to that cell.

What it doesn't cover

• —Does not cover immunoglobulins that do not have a toxic moiety attached to them.
• —Does not cover toxic therapies where the toxic agent is not specifically delivered by an immunoglobulin.
• —Does not cover immunoglobulins that target cells by binding to something other than an MHC-peptide complex.
• —Does not cover immunoglobulins that bind to MHC-peptide complexes that are equally common on both healthy and diseased cells.
• —Does not cover immunoglobulins that target aberrant cells but are not specifically designed to bind to an MHC-peptide complex.

The clever bit

The novelty lies in precisely targeting 'aberrant cells' using an immunoglobulin that binds to an 'MHC-peptide complex' that is *preferentially* found on these diseased cells, and then delivering a 'toxic moiety' directly to them. This allows for highly specific destruction of harmful cells while sparing healthy ones.

Why it matters

This technology aims to create highly targeted therapies for serious diseases like cancer and autoimmune disorders. By specifically delivering a toxic payload to aberrant cells, it seeks to minimize harm to healthy tissues, potentially reducing severe side effects often associated with traditional treatments like chemotherapy. This precision targeting could lead to more effective and safer treatment options for patients.

Real-world examples

• 1.Antibody-Drug Conjugates (ADCs) in cancer therapy
• 2.Targeted immunotherapies for specific tumor types
• 3.Experimental treatments for autoimmune diseases using targeted cell depletion